Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, April 12, 2022
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
Matthew Harrison Maintained (SRPT) at Hold with Decreased Target to $77 on, Apr 12th, 2022
Matthew Harrison of Morgan Stanley, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Hold with Decreased Target from $80 to $77 on, Apr 12th, 2022.
Matthew has made no other calls on SRPT in the last 4 months.
There are 3 other peers that have a rating on SRPT. Out of the 3 peers that are also analyzing SRPT, 0 agree with Matthew's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Matthew
- Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy and Held Target at $105 on, Thursday, March 3rd, 2022
- Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $150 on, Wednesday, March 2nd, 2022
- Gil Blum of "Needham" Maintained at Strong Buy with Decreased Target to $150 on, Wednesday, January 5th, 2022
